Targeting Stat3 in cancer therapy

Anti-Cancer Drugs

Volumn 16, Issue 6, 2005, Pages 601-607

  Jing, Naijie ^a   Tweardy, David J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer therapy; G quartet oligodeoxynucleotide; Stat3

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CELL CYCLE PROTEIN; CUCURBITACIN I; CYCLIN D1; INHIBITOR OF APOPTOSIS PROTEIN; JSI 124; MYC PROTEIN; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; OLIGODEOXYNUCLEOTIDE DERIVATIVE; PHOSPHOPEPTIDE; POLYETHYLENEIMINE; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN TYROSINE KINASE INHIBITOR; STAT1 PROTEIN; STAT3 PROTEIN; SURVIVIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CANCER SURVIVAL; CANCER THERAPY; COMPARATIVE STUDY; DRUG BINDING SITE; DRUG DELIVERY SYSTEM; DRUG DNA BINDING; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TARGETING; HUMAN; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; RAT; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION INITIATION;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; CELL CYCLE PROTEINS; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LIGANDS; NEOPLASMS; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHOPEPTIDES; PLASMIDS; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAINS; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATION (GENETICS); TRITERPENES; TYRPHOSTINS;

EID: 20844444135     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200507000-00002     Document Type: Review

References (74)

1. Darnell Jr JE. STATs and gene regulation. Science 1997; 277:1630-1635.
2. Zhong Z, Wen Z, Darnell Jr JE. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994; 264:95-98.
3. Ihle JN. Cytokine receptor signaling. Nature 1995; 377:591-594.
4. Bromberg JF, Horvath CM, Wen Z, Schreiber RD, Dannell Jr JE. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci USA 1996; 93:7673-7678.
5. Cressman DE, Greenbaum LE, DeAngelis RA, et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996; 274:1379-1383.
6. Fukada T, Hibi M, Yamanaka Y, et al. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity 1996; 5:449-460.
7. h2 cells in Stat4-deficient mice. Nature 1996; 382:174-177.
8. Stephens JM, Morrison RF, Pilch PF. The expression and regulation of STATs during 3T3-L1 adipocyte differentiation. J Biol Chem 1997; 271:10441-10444.
9. Planas AM, Berruezo M, Justicia C, Barron S, Ferrer I. Stat3 is present in the developing and adult rat cerebellum and participates in the formation of transcription complexes binding DNA at the cis-inducible element. J Neurochem 1997; 68:1345-1351.
10. Takeda K, Noguchi K, Shi W, et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA 1997; 94:3801-3804.
11. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000; 19:2548-2556.
12. Smithgall TE, Briggs SD, Schreiner S, Lerner EC, Cheng H, Wilson MB. Control of myeloid differentiation and survival by Stats. Oncogene 2000; 19:2612-2618.
13. Akira S. Roles of STAT3 defined by tissue-specific gene targeting. Oncogene 2000; 19:2607-2611.
14. Zhang X, Blenis HC, Li HC, Schindler C, Che-Kiang C. Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science 1995; 267:1990-1994.
15. Braunstein J, Brutsaert S, Olson S, et al. STATs dimerize in the absence of phosphorylation. J Biol Chem 2003; 278:34133-34140.
16. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000; 19:2474-2488.
17. Bromber JF. Activation of STAT proteins and growth control. BioEssays 2001; 23:161-169.
18. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumor provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002; 8:945-954.
19. Becker S, Groner B, Muller C. Three-dimensional structure of the Stat3β homodimer bound to DNA. Nature 1998; 394:145-150.
20. Chen X, Vinkemeier U, Zhao Y, Jeruzalmi D, Darnell JE, Kuriyan J. Crystal structure of a tyrosine phosphorylated Stat-1 dimer bound to DNA. Cell 1998; 93:827-839.
21. Wegenka UM, Lutticken C, Buschmann J, et al. The interleukin-6-activated acute-phase response factor is antigenically and functionally related to members of the signal transducer and activator of transcription (STAT) family. Mol Cell Biol 1994; 14:3186-3196.
22. Lutticken C, Wegenka UM, Yuan J, et al. Association of transcription factor APRF and protein kinase jak 1 with the interleukin-6 signal transducer gp130. Science 1994; 263:89-92.
23. Zhong Z, Wen Z, Darnell JE. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994; 264:95-98.
24. Raz R, Durbin JE, Levy DE. Acute phage response factor and additional member of the interferon-stimulated gene factor 3 family integrate diverse signals from cytokines, interferons, and growth factor. J Biol Chem 1994; 269:24391-24395.
25. Akira S, Nishio Y, Inoue M, et al. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 1994; 77:63-71.
26. Schindler C, Darnell Jr JE. Transcriptional responses to polypeptide ligands: the JAK-ATAT pathway. Annu Rev Biochem 1995; 64:621-651.
27. 1 to S cell-cycle transition. EMBO J 1998; 15:6670-6677.
28. Chakraborty A, Tweardy DT. Stat3 and G-CSF-induced myeloid differentiation. Leuk Lymph 1998; 30:433-442.
29. de Koning JP, Soede-Bobok AA, Ward AC, et al. Stat3-mediated differentiation and survival and of myeloid cells in response to granulocyte colony-stimulating factor: role for the cyclin-dependent kinase inhibitor p27 (Kip1). Oncogene 2000; 19:3290-3298.
30. Shimozaki K, Nakajima N, Hirano T, Nagata S. Involvement of STAT3 in the granulocyte colony-stimulating factor-induced differentiation of myeloid cells. J Biol Chem 1997; 272:25184-25189.
31. Shirogane T, Fukada T, Muller JM, Shima DT, Hibi M, Hirano T. Synergistic roles for pim-1 and c-Myc in Stat3-mediated cell cycle progression and antiapoptosis. Immunity 1999; 11:709-719.
32. Akira S. Roles of STAT3 defined by tissue-specific gene targeting. Oncogene 2000; 19:2607-2611.
33. Garcia R, Jove R. Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. J Biomed Sci 1998; 5:79-85.
34. Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, Schwartz J, Jove R. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995; 268:81-83.
35. Bromberg JF, Horvoth CM, Basser D, Lathem WW, Darnell Jr JE. Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 1998; 18:2553-2558.
36. Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP, Jove R. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 1988; 18:2545-2552.
37. Broberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell, 1999; 98:295-303.
38. Mora LB, Buettner R, Seigne J, et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 2002; 62:6659-6666.
39. Dolled-Filhart M, Camp RL, Kowalski DP, Smith BL, Rimm DL. Tissue microarray analysis of signal transducers and activatior of transcription 3 and phospho-state 3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res 2003; 9:594-600.
40. Nagpal JK, Mishra R, Das BR. Activation of Stat3 as one of early events in tobacco chewing-mediated oral carcinogenesis. J Am Cancer Soc 94:2393-2400.
41. Hsiao J-R, Jin Y-T, Tsai T, Shiau A-L, Wu C-L, Su W-C. Constitutive activation of Stat3 and Stat5 is present in majority of nasopharyngeal carcinoma and correlates with better prognosis. Br J Cancer 2003; 89:344-349.
42. Boise LH, Gonzalez-Garcia M, Postema CE, et al. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74:597-608.
43. L is the major bcl-x mRNA form expressed during murine development and its product localizes to mitochondria. Development 1994; 120:3033-3042.
44. L: a little bit to this and a little bit to STAT. Curr Opin Oncol 2001; 12:543-549.
45. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2:647-656.
46. Epling-Burnette PK, Liu JH, Catlett-Falcone R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decrease Mcl-1 expression. J Clin Invest 2001; 107:351-362.
47. Zhou P, Qian L, Kozopas KM, Craig RW. Mcl-1, a bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood 1997; 89:630-643.
48. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3:46-54.
49. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood. 2003; 101:1535-1542.
50. Calo V, Migliavacca M, Bazan V, et al. STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol. 2003; 197:157-168.
51. 1: normal and abnormal functions. Endocrinology 2004; 145:5439-5447.
52. Spencer CA, Groudine M. Control of c-myc regulation in normal and neoplastic cells. Adv Cancer Res 1991; 56:1-48.
53. Marcu KB, Bossone SA, Patel AJ. myc function and regulation. Annu Rev Biochem 1992; 61:809-860.
54. Facchini LM, Penn LZ. The molecular role of Myc in growth and transformation: recent discoveries lead to new insights. FASEB J 1998; 12:633-651.
55. Niu G, Wright KL, Huang M, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002; 21:2000-2008.
56. Chen H, Ye D, Xie X, Chen B, Lu W. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gene Oncol 2004; 94:630-635.
57. Epling-Burnette PK, Liu JH, Catlett-Falcone R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 2001; 107:351-362.
58. Grandis JR, Drenning SD, Zeng Q, Watkins SC. Constitutive activation of Stat3 signalingabrogets apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 2000; 97:4227-4232.
59. Meyden N, Grunberger T, Harjit D, et al. inhibition of acute lymphoblastic leusemia by a Jak-2 inhibitor. Nature 1996; 379:645-648.
60. Catlett-Falcone R, Dalton WS, Joce R. STAT proteins as novel targets for cancer therapy. Curr Opin Oncol 1999; 11:490-496.
61. Burdelya L, Catlett-Falcone R, Levitzki A, et al. Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone. Mol Cancer Ther 2002; 1:893-899.
62. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 2003; 63:1270-1279.
63. Turkson J, Ryan D, Kim JS, et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem 2001; 276:45443-45455.
64. Ren Z, Cabell LA, Schaefer TS, et al. Identification of a high-affinity phosphopeptide inhibitor of stat3. Bioorg Med Chem Lett 2003; 13:633-636.
65. Shao H, Cheng HY, Mastrangelo MA, et al. Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res 2003; 63:3923-3930.
66. Wiederkehr-Adam M, Ernst P, et al. Characterization of phosphopeptide motifs specific for the Src homology 2 domains of signal transducer and activator of transcription 1 (STAT1) and STAT3. J Biol Chem 2003; 278:16117-16128.
67. Shao H, Xu X, Mastrangelo MA, et al. Structural requirements for signal transducer and activator of transcription 3 binding to phosphotyrosine ligands containing the YXXQ motif. J Biol Chem 2004; 279:18967-18973.
68. Jing N, Li Y, Xu X, Li P, Feng L, Tweardy D. Targeting Stat3 with G-quartet oligonucleotides in human cancer cells. DNA Cell Biol 2003; 22:685-696.
69. Jing N, Li Y, Xiong W, Sha W, Jing L, Tweardy DJ. G-quartet oligonucleotides: a new class of Stat3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis. Cancer Res 2004; 64:6603-6609.
70. Bromberg JF, Horvath CM, Wen Z, et al. Transcriptionally active Stal1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci USA 1996; 93:7673-7678.
71. Xu X, Fu XY, Plate J, et al. IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res 1998; 58:2832-2837.
72. Jing N, Xiong W, Guan Y, Pallansch L, Wang S. Potassium dependent folding: a key to intracellular delivery of G-quartet oligonucleotides as HIV inhibitors. Biochemistry 2002; 41:5397-5403.
73. Leong PL, Andrews GA, Johnson DE, et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA 2003; 100:4138-4143.
74. Sano S, Chan KS, Carbajal S, et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 2005; 11:43-49.